Johnson & Johnson (JNJ) - Comprehensive Stock Analysis Report
📋 Investment SnapshotIs JNJ a buy right now? The 10-second read
Reason: Strong business, constructive setup. Expected Return is the upside to the analyst price target; full rationale is detailed below.
📌 Is JNJ a Buy right now?
According to Ultra Stock Analysis Pro, Johnson & Johnson (JNJ) reads ACCUMULATE for a new position and HOLD for an existing one (Signal Strength: 3/7 (last fired 2026-09-04, 21d ago)). The long-term fundamentals are stable (P/E: 31.5, Revenue Growth: +6.6%), while short-term technicals show a bullish trend (RSI: 57). Consider waiting for support confirmation near $272.15 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open JNJ Analysis ↗
⚡ QUICK DECISIONShould you buy, hold or wait on JNJ stock today?
- Reward:risk: 1.47:1 to the analyst target $286.41, against a stop at $260.90.
- Model timing: GREEN · BULLISH, WATCHING FOR ENTRY · EXTENDED.
- Stop loss: the Conservative fixed 2.0x ATR stop sits at $260.90, 3.8% below the current $271.22.
- Growth vs. valuation: revenue +6.6% YoY with a 29.2% operating margin, at a forward P/E of 23.5x.
- Wall Street: average target $286.41 (+5.6%) from 16 Buy, 6 Hold, 1 Sell ratings.
- Key levels: nearest support $265.36 (-2.2%), nearest resistance $272.15 (+0.3%).
💡 Why This Signal ExistsWhy does JNJ carry this rating?
JNJ carries a ACCUMULATE rating because valuation and fundamentals remain attractive (Investment Quality 77/100) and the trend is strong (ADX 25), but relative strength has slipped over the past month and only a partial setup is building (Signal Strength 3/7). A breakout above $272.15 on improving volume would upgrade the signal toward BUY; a break below $265.36 would mark deeper weakness.
🎯 CONSENSUS HUDWhat is the Wall Street analyst consensus on JNJ?
The call itself, and the readings behind it. Details read supportive / caution / headwind.
Action plan
If you own it: HOLD — Thesis intact, but no edge in adding here.
If you don't: ACCUMULATE — Reward:risk improves to 2.04:1 at $265.36.
🎯 Intelligent Stop Loss Strategy
Current Price
$271.22
Buy Stop Loss
$260.90
Distance: 4%
Conservative 2.0x
Position Stop Loss
$263.48
Distance: 3%
Hybrid 1.50x
ATR 14 Day
$5.16
Volatility
ADX Strength
16.6
Weak/No Trend
Position up +13% - Adaptive strategy adjusts for momentum
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
🔮 FUTURE PRICE SCENARIOS (AI Forecast)Where could JNJ stock go over the next week?
To assist with risk management, here are the three most probable paths for JNJ over the next trading week:
🟢 The Bull Case (Probability: 42%)
If JNJ reclaims the $272.15 resistance level, algorithmic targets shift to $286.41. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 39%)
Failure to hold the $265.36 support level triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $257.67 liquidity zone (-5.0% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 17 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $265.36 and $272.15 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
⚠️ RISK HUD — DEEP DIVEWhat are the biggest risks of buying JNJ now?
Five risk axes scored LOW / MODERATE / HIGH, then the mitigation that follows from them.
📊 BUY-SIDE HUDHow much JNJ should you own, and can you trade it at size?
Portfolio-management read: how much to own, what the historical edge is, and whether the position can be traded at size. Details below read supportive / caution / headwind; grey is context, not a verdict.
🎯 THE TWO VERDICTSShould you buy JNJ now, and should you hold it if you already own it?
Two questions, computed separately: the entry verdict never reads whether a position is open, and the position verdict never reads entry quality.
Price vs. its 50-day trend — CONSTRUCTIVE
Nothing fired. ○ context, does not decide the badge
📏 ENTRY MATHWhat is the reward-to-risk on JNJ right now?
Reward is measured to the analyst target $286.41; risk to the 2x ATR entry stop at $260.90. Both legs are pre-trade, so the ratio means the same thing whether or not the model is holding.
Analyst figures are the consensus mean of the panel this report tracks. Other services poll a different set of analysts, so a target quoted elsewhere — including on our own live scanner — can sit a few percent either side of this one, and the reward leg moves with it.
A second analyst panel reads JNJ differently, and the two readings are materially different. The panel above averages $286.41 (1.47:1); an independent panel averages $277.91 (0.65:1). Neither is the correction of the other — they poll different analysts. Treat the reward leg as a range, not a point.
| Entry at | Price | Risk | Reward | R:R |
|---|---|---|---|---|
| Model entry held since 2026-06-12 · +13.2% · against its own $230.97 stop, to TODAY's target — a fact, not a recommendation | $239.69 | $8.72 | $46.72 | 5.36:1 |
| Today at $271.22 | $271.22 | $10.32 | $15.19 | 1.47:1 |
| Accumulation anchor nearest level worth waiting for · zone $265.36–$270.67 · stop $255.04 | $265.36 | $10.32 | $21.05 | 2.04:1 |
Entry zones
📈 SELL-SIDE HUDIs JNJ stock overvalued or undervalued?
Research read: Johnson & Johnson · Healthcare · Drug Manufacturers - General. What the business is worth and where the Street stands. Details below read supportive / caution / headwind; grey is context, not a verdict.
🧭 Investment Quality vs. Entry QualityHow does JNJ's investment quality compare to its entry quality?
Two independent reads: how good the business is (fundamentals) vs. how stretched the price is against its recent range. Entry Quality is a mean-reversion score — it marks a stock down for trading near the top of its range. It is not the model's timing call, which is GREEN · BULLISH, WATCHING FOR ENTRY · EXTENDED and appears in the Consensus HUD above.
JNJ: Investment Quality 77/100 vs. Entry Quality 56/100 — weigh business strength against the current setup.
🧮 Factor AttributionWhat is actually driving JNJ's rating?
What is driving the view — every factor's signed contribution to one net score. Green adds to the bull case; red detracts.
| Factor | Contribution | Pts |
|---|---|---|
| Profitability Margin 21%, ROE 26% | +14 | |
| Trend EMA bullish, ADX 25 | +12 | |
| Revenue Growth +7% YoY | +4 | |
| Sentiment Bullish | +4 | |
| Relative Strength +2.6% vs benchmarks (3M) | +3 | |
| Valuation Fwd P/E 23.5, PEG 2.3 | +0 | |
| Volatility ATR 1.9% of price | +0 | |
| Earnings Growth -1% YoY | -1 | |
| Momentum RSI 61, MACD bearish | -5 |
Net Factor Score: +31 — Net bullish. This weighs the broad bull/bear case; the entry signal (Signal Strength) governs timing — a strong factor score can still read WAIT until a setup triggers.
🏆 Relative StrengthIs JNJ outperforming the S&P 500 and its sector?
The stock's return minus each benchmark's return. Positive = outperforming = leadership; negative = lagging. Relative strength is one of the most durable signals in quantitative research.
| Benchmark | 1-Mo | 3-Mo | 6-Mo |
|---|---|---|---|
| S&P 500 (SPY) | -0.5% | +1.0% | -5.6% |
| Healthcare (XLV) | +1.7% | +0.2% | -3.5% |
| Pharma (XPH) | +9.6% | +6.7% | -9.4% |
JNJ 3-month return: +7.0% · Leadership: BROAD LEADER — outperforming the market, its sector, and peers
🤖 ML ProbabilityWhat is the probability JNJ stock closes higher?
A gradient-boosted model's estimated probability that price closes higher over each horizon (directional estimate, not a guarantee).
📊 Valuation & Fundamentals vs Drug Manufacturers - General (10 peers)Is JNJ cheap or expensive versus its sector peers?
● Top 25% in sector ● Middle 50% ● Bottom 25% — each value colored by its rank among 10 Drug Manufacturers - General peers; "med" is the peer median.
⚔️ JNJ vs. Its Closest PeersHow does JNJ compare to PFE and its other closest peers?
The closest business match first, then the nearest by market cap within Drug Manufacturers - General from the live sector screener. Industry classification alone is not enough — it files JNJ beside companies in a different line of business — so the direct competitor is seeded explicitly. Green marks the best reading in each row, red the worst.
| Metric | JNJ (this report) | PFE | ABBV | MRK |
|---|---|---|---|---|
| Market Cap | $653.6B | $163.4B | $467.1B | $367.1B |
| Revenue Growth (YoY) | +6.6% | +2.6% | +10.2% | +5.1% |
| Forward P/E (FY2026E) | 23.5x | 9.6x | 18.8x | 54.3x |
| PEG Ratio (FY2026–FY2027E CAGR) | 2.29 | — | 1.45 | 1.38 |
| Operating Margin | 29.2% | 27.9% | 40.0% | -0.2% |
| Trend Strength (ADX) | 16.6 | 25.7 | 18.7 | 30.1 |
PFE (Pfizer Inc. — closest business match), ABBV (AbbVie Inc.), MRK (Merck & Co., Inc.). Peers marked “closest business match” come from the curated rival map; the rest are the nearest by market cap in the same industry. ADX is shown where recent price data is already on file for that peer.
🎯 ANALYST PRICE TARGETSHow high could JNJ go? The full target range
| Average Target: | $286.41 | High Target: | $320.00 |
| Current Price: | $271.22 | Low Target: | $255.00 |
| Upside to Average: | +5.6% | Number of Analysts: | 23 |
🔔 ANALYST RATING CHANGESHave analysts upgraded or downgraded JNJ recently?
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| Guggenheim | REITERATED | Buy → Buy | Jul 17, 2026 |
| RBC Capital | REITERATED | Outperform → Outperform | Jul 16, 2026 |
News Sentiment (14-Day)What is the latest news sentiment on JNJ?
Overall Score: 4.2/10 - Bullish
Bullish Articles (Top 5 of 3)
- Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
Insider Monkey • Sep 27Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is e...
Source: https://finance.yahoo.com/healthcare/articles/gilead-johnson... - AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool • Sep 25AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition ...
Source: https://www.fool.com/coverage/better-buy/2026/09/25/abbvie-v... - Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
Proactive • Sep 25Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a...
Source: https://www.proactiveinvestors.com/companies/news/1099148/jo...
📊 Sentiment Interpretation
The news sentiment is strongly bullish, indicating positive market perception and favorable coverage. This suggests growing investor confidence and potential upward momentum. Consider this as a supporting factor for bullish positions, but verify with technical and fundamental analysis.
📊 Strategy Comparison: Conservative vs Adaptive
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Adaptive adjusts stops based on position profit (tighter as profit grows).
Conservative Strategy
OPEN POSITIONFixed 2.0x ATR Stop Loss
Entry: $239.69 on 2026-06-12
Confluence: 4/7 (11d before entry)
Stop Loss: $260.90
Backtest Results (Since 2018):
Past Win Rate
71%
Past Total Return
+47.8%
Max Drawdown
-9.8%
Avg Trade
+4.6%
Trades
17
Adaptive Strategy
OPEN POSITIONAdaptive ATR Stop Loss (1.0-2.75x)
Entry: $239.69 on 2026-06-12
Confluence: 4/7 (11d before entry)
Stop Loss: $263.48
Backtest Results (Since 2018):
Past Win Rate
64%
Past Total Return
+56.8%
Max Drawdown
-10.1%
Avg Trade
+3.8%
Trades
22
EXECUTIVE SUMMARY - Essential MetricsWhat are the key metrics for JNJ stock?
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $271.22 | Market Cap | $653.6B |
| Past Win Rate (Backtest) | 70.6% (17 trades) | Forward P/E (FY2026E) | 23.5x |
| Past Total Return | +47.8% | Analyst Target | $286.41 |
| RSI / Trend Strength | 57 / 17 | Upside to Target | +5.6% |
| MACD Signal | Bullish | Revenue Growth | +6.6% |
| Profit Factor | 2.24 | Institutional Own. | 76.7% |
| Position Entry | 2026-06-12 @ $239.69 | Analyst Ratings | 16 Buy / 6 Hold / 1 Sell |
| Open Position Past P&L | +13.2% |
🤖 ALGORITHMIC CONVICTION & METHODOLOGYHow is the JNJ rating calculated?
Why this rating?
The Ultra Stock Analysis algorithm has assigned a ACCUMULATE entry rating to JNJ based on a confluence of 3 distinct factors:
- Technical Momentum: The RSI (57) is currently in neutral range.
- Trend Strength: ADX at 17 indicates weak/consolidating conditions (<20). News sentiment is neutral (Bullish).
- Volatility Profile: The ATR ($5.16) indicates moderate volatility (1.9% of price), suggesting potential moves of 3.8%+ on breakouts.
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 71% of the time across 17 historical trades over a medium-term (months) hold period, with an average return of +4.6% per trade.
Firing now — EMA Trend Alignment (2) · Strong Trend (ADX > 25) (1).
Not firing: Valid Breakout, RSI Bullish Divergence, MACD Bullish Divergence, High Volume (>1.5×), RSI Oversold, Below Lower Bollinger, Volume Accumulation.
📊 How the score works — the full checklist, what each signal means, and why 3/7 can read low in an uptrend
Signal Strength is a tactical entry-timing score, not a trend or fundamentals grade. It only adds points from setups that flag a fresh reason to enter — breakouts, momentum divergences, and oversold/volume/volatility extremes. Trend direction and fundamentals are scored in their own sections above. A setup must reach 3+ points to register as a signal and 5+ for a strong BUY. Individual boxes below can be checked — a stacked EMA trend alone is worth 2 points — without crossing the 3-point bar; when that happens the registered Signal Strength stays at 3/7, meaning no new entry trigger today — not a bearish call.
| Signal | Pts | What it flags | Now |
|---|---|---|---|
| Valid Breakout | 3 | Close breaks above the 20-day high on >1.5× volume | ✗ |
| EMA Trend Alignment | 2 | EMA20 > EMA50 > EMA200 (stacked uptrend) | ✓ |
| RSI Bullish Divergence | 2 | Price firms while RSI was falling — a reversal setup | ✗ |
| MACD Bullish Divergence | 2 | Price firms while MACD was falling — a reversal setup | ✗ |
| Strong Trend (ADX > 25) | 1 | ADX > 25 confirming the stacked EMAs | ✓ |
| High Volume (>1.5×) | 1 | Volume surge confirming the move | ✗ |
| RSI Oversold | 1 | RSI < 30 — stretched to the downside (bounce setup) | ✗ |
| Below Lower Bollinger | 1 | Close below the lower band (mean-reversion setup) | ✗ |
| Volume Accumulation | 1 | Up-volume divergence — quiet accumulation | ✗ |
This is why JNJ can show a bullish EMA trend and solid fundamentals while Signal Strength reads 3/7: those are already-in-trend and value measures, whereas this score fires only on a new tactical setup (an oversold bounce, a divergence, or a high-volume breakout) — none of which is present on the latest bar.
❓ JNJ — Common Questions
— 5 answers, each drawn from the figures above
Every answer below is generated from the same figures as the report above, as of the data date on the cover.
📊 APPENDIX A - Complete Technical Indicators
Comprehensive technical data for quantitative analysis, grouped by what each indicator measures. Price leads; the three Bollinger bands sit together with the band position that reads them.
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Price & Volume | |||
| Current Price | $271.22 | Volume | 4.1M |
| Avg Volume | 7.0M | Beta | 0.23 |
| Trend | |||
| EMA 20 | $268.80 | EMA 50 | $263.54 |
| EMA 200 | $237.40 | VWAP | $270.91 |
| Trend Strength (ADX) | 16.60 | Distance from EMA 20 | +0.9% |
| Momentum | |||
| RSI (14) | 57.23 | MACD | 1.51 |
| MACD Signal | 1.77 | MACD Histogram | -0.26 |
| Stochastic %K | 59.16 | Stochastic %D | 50.63 |
| Bollinger Bands (20, 2σ) | |||
| Bollinger Upper | $276.45 | Bollinger Middle | $269.64 |
| Bollinger Lower | $262.83 | Band Position | 61.6% (0% = lower band, 100% = upper) |
| Volatility | |||
| ATR (14) | $5.16 | ATR as % of price | 1.9% |
| Signal | |||
| Confluence Score | 3/7 (last fired 2026-09-04, 21d ago) | Trade Signal | None in the last 30 days |
💼 APPENDIX B - Complete Fundamental Metrics
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $653.6B | Revenue | $97.9B |
| Forward P/E (FY2026E) | 23.5 | Revenue Growth | +6.6% |
| Trailing P/E | 31.5 | Gross Margin | 68.1% |
| Price/Sales | 6.67 | Operating Margin | 29.2% |
| Price/Book | 7.69 | Profit Margin | 21.5% |
| PEG Ratio (FY2026–FY2027E CAGR) | 2.29 | ROE | 25.7% |
| Enterprise Value | $681.9B | Free Cash Flow | $16.9B |
| EPS (Forward) | $11.53 | Dividend Yield | 1.98% |
| 52-Week Range | $179.80 - $281.07 | ||
📈 APPENDIX C - Complete Trade History & Backtest Results
Comprehensive Trading Performance and Position Details
Backtest Performance Metrics
Current Open Position
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-06-12 | $239.69 | +13.16% | $230.97 |
Recent Trade History (Last 10 Trades)
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2023-03-09 | 2023-04-05 | $136.85 | $149.85 | +9.50% | Win |
| 2023-04-14 | 2023-05-16 | $150.06 | $144.18 | -3.92% | Loss |
| 2023-06-15 | 2023-07-12 | $149.27 | $144.12 | -3.45% | Loss |
| 2023-07-20 | 2023-08-10 | $153.51 | $156.96 | +2.25% | Win |
| 2023-10-27 | 2023-12-04 | $133.70 | $147.06 | +9.99% | Win |
| 2023-12-08 | 2024-04-16 | $142.94 | $134.72 | -5.75% | Loss |
| 2024-07-18 | 2024-08-05 | $146.13 | $151.61 | +3.75% | Win |
| 2024-12-20 | 2025-04-10 | $137.96 | $143.13 | +3.74% | Win |
| 2025-07-16 | 2025-12-15 | $159.97 | $210.78 | +31.76% | Win |
| 2026-01-14 | 2026-04-24 | $215.09 | $225.09 | +4.65% | Win |
Summary: 17 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Run a Live Real-Time Scan of JNJ
This report is a snapshot through 2026-09-25. Get current technicals, fresh AI news sentiment, and up-to-the-minute stop-loss levels for JNJ — free, no signup.
▶ Run Live JNJ Analysis →